Stivarga: a new oral multikinase inhibitor

Stivarga (regorafenib) is indicated in metastatic colorectal cancer previously treated with fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy, or when these therapies are not suitable.

The recommended dose of Stivarga is 160mg once daily after a light low-fat meal on days 1-21 of a 28-day treatment cycle
The recommended dose of Stivarga is 160mg once daily after a light low-fat meal on days 1-21 of a 28-day treatment cycle

PHARMACOLOGY

Regorafenib is an oral tumour deactivation agent that inhibits multiple protein kinases, including those involved in tumour angiogenesis, oncogenesis and the tumour microenvironment.1,2

CLINICAL STUDIES

The safety and efficacy of regorafenib were evaluated in the double-blind, phase III CORRECT study involving 760 patients with metastatic colorectal cancer that had progressed after failure of standard therapy.1,2

Patients were randomised to receive best supportive care plus regorafenib 160mg (n=505) or placebo (n=255) once daily for the first 3 weeks of each monthly treatment cycle. Treatment was continued until disease progression or unacceptable toxicity occured. The primary outcome measure was overall survival.1,2

Survival increased

Regorafenib produced a significant improvement in overall survival compared with placebo, of 6.4 versus 5 months (HR 0.77, 95% CI 0.64–0.94, p=0.0052). A significant improvement in progression-free survival, a secondary endpoint, was also observed (HR 0.494, p<0.000001).1,2

Safety profile

The most common adverse effects observed in patients receiving regorafenib were hand-foot skin reaction, fatigue, diarrhoea, hypertension and rash.1,2

References:

  1. Stivarga Summary of Product Characteristics, August 2013.
  2. Grothey A et al. Lancet 2013; 381: 303–12.

View Stivarga drug record

Further information: Bayer plc

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New shingles vaccine awaits decision on NHS use

New shingles vaccine awaits decision on NHS use

Shingrix, which is now available privately in the UK,...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...